IL280177B2 - Use of riluzole prodrugs for the treatment of Alzheimer's disease - Google Patents

Use of riluzole prodrugs for the treatment of Alzheimer's disease

Info

Publication number
IL280177B2
IL280177B2 IL280177A IL28017721A IL280177B2 IL 280177 B2 IL280177 B2 IL 280177B2 IL 280177 A IL280177 A IL 280177A IL 28017721 A IL28017721 A IL 28017721A IL 280177 B2 IL280177 B2 IL 280177B2
Authority
IL
Israel
Prior art keywords
disease
pharmaceutical composition
riluzole
study
alzheimer
Prior art date
Application number
IL280177A
Other languages
English (en)
Hebrew (he)
Other versions
IL280177A (en
IL280177B1 (en
Inventor
Vladimir Coric
Robert Berman
Irfan Qureshi
Original Assignee
Biohaven Therapeutics Ltd
Vladimir Coric
Robert Berman
Irfan Qureshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Vladimir Coric, Robert Berman, Irfan Qureshi filed Critical Biohaven Therapeutics Ltd
Publication of IL280177A publication Critical patent/IL280177A/en
Publication of IL280177B1 publication Critical patent/IL280177B1/en
Publication of IL280177B2 publication Critical patent/IL280177B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL280177A 2018-07-22 2019-07-20 Use of riluzole prodrugs for the treatment of Alzheimer's disease IL280177B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (3)

Publication Number Publication Date
IL280177A IL280177A (en) 2021-03-01
IL280177B1 IL280177B1 (en) 2024-09-01
IL280177B2 true IL280177B2 (en) 2025-01-01

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280177A IL280177B2 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs for the treatment of Alzheimer's disease

Country Status (14)

Country Link
US (1) US12161633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823616A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021530543A (cg-RX-API-DMAC7.html)
KR (1) KR20210034621A (cg-RX-API-DMAC7.html)
CN (1) CN112469408A (cg-RX-API-DMAC7.html)
AU (1) AU2019310013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107215A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190308A1 (cg-RX-API-DMAC7.html)
IL (1) IL280177B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021000515A (cg-RX-API-DMAC7.html)
PH (1) PH12021550043A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100385YA (cg-RX-API-DMAC7.html)
WO (1) WO2020023324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
BR112023016690A2 (pt) * 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064775A1 (en) * 2010-03-02 2013-03-14 Universite D'auvergne Clermont I Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
US20180037557A1 (en) * 2015-03-03 2018-02-08 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs riluzole and their method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275525B2 (en) * 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
HRP20220237T1 (hr) * 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US12029731B2 (en) * 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US10751345B2 (en) * 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064775A1 (en) * 2010-03-02 2013-03-14 Universite D'auvergne Clermont I Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
US20180037557A1 (en) * 2015-03-03 2018-02-08 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs riluzole and their method of use

Also Published As

Publication number Publication date
AU2019310013B2 (en) 2025-01-02
WO2020023324A1 (en) 2020-01-30
MX2021000515A (es) 2021-06-08
SG11202100385YA (en) 2021-02-25
IL280177A (en) 2021-03-01
IL280177B1 (en) 2024-09-01
CA3107215A1 (en) 2020-01-30
JP2021530543A (ja) 2021-11-11
EP3823616A1 (en) 2021-05-26
EP3823616A4 (en) 2022-05-04
NZ772009A (en) 2026-02-27
BR112021000768A2 (pt) 2021-05-11
AU2019310013A1 (en) 2021-02-11
PH12021550043A1 (en) 2021-09-20
KR20210034621A (ko) 2021-03-30
US12161633B2 (en) 2024-12-10
CN112469408A (zh) 2021-03-09
MX2024010655A (es) 2024-09-11
EA202190308A1 (ru) 2021-05-19
US20210290599A1 (en) 2021-09-23
JP2025093952A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
US12161633B2 (en) Use of riluzole prodrugs to treat alzheimer's disease
Kiernan et al. Amyotrophic lateral sclerosis
Landtblom et al. Short‐term memory dysfunction in Kleine–Levin syndrome
US20200085816A1 (en) Lsd for the treatment of alzheimer's disease
US11123332B2 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
Reid et al. A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence
Growdon et al. Piracetam combined with lecithin in the treatment of Alzheimer's disease
CN105832733A (zh) 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
US20240082340A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
KR20150119089A (ko) 알츠하이머병 치료 방법에 사용하기 위한 헬리카제-프리마제 억제제
US12201618B2 (en) Use of riluzole prodrugs to treat Alzheimer's disease
Zhang et al. Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice
AU2023286504A1 (en) Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
EA049330B1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
Ramos-Quiroga et al. Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults: JA Ramos-Quiroga et al.
WO2024006537A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
FENG et al. Clinical analysis of 30 cases with Stevens-Johnson syndrome
Bhattacharyya et al. P0361-Delta-9-tetrahydrocannabinol modulates parahippocampal and ventral striatal activity during processing of verbal memory
Gracious et al. Child and Adolescent Program of the 42nd Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, Florida, June 10–13, 2002
Zoing et al. Motor neurone disease Caring for the patient in general practice
Pillai The Role of the Serotonin 1A Receptor in Mood Disorders
DelaRaillere et al. Bibliography Current World Literature Vol 15 No
HK1252154B (en) Extended release pharmaceutical compositions of levetiracetam
CA3193824A1 (en) Riluzole for the treatment of alzheimer's disease